Available Technologies
Partner with us to bring new technology to life
Some of this research is developed into startup companies that need investment or partners to further advance their research and development, other research is available for companies around the world so they can access cutting-edge innovation and expert collaboration that can help accelerate their business.
To find out more about our startups, many of which are looking for investment, check out our Investment Portfolio.
Drugs, vaccines and drug delivery
| Therapeutic Area | Name | Description | Status | Contact |
|---|---|---|---|---|
| Regenerative and tissue engineering | Skin Engineering |
System for rapid growth of full-thickness autologous skin.
Download PDF |
Available for licensing | |
| Vaccines and drug delivery | High volume needleless injection | A multijet, needleless injector, that can spread the injection volume over a larger area simultaneously, allowing higher delivery volumes and enabling self administration of a wider range of therapies, potentially decreasing patient load at clinics. | Available for licensing | |
| Vaccines and drug delivery | Orally available peptide formulation |
A non-aqueous microemulsion which encapsulates the water soluble peptide and protects it from enzymatic degradation until it can be absorbed systemically. This technology has been shown to work in in vivo models. |
Available for licensing | |
| Oncology | cKit | Treatment-resistant gastrointestinal stromal tumours (GIST) can often be driven by mutations in disease-causing protein kinases like c-KIT. A new kinase inhibitor selectively targets mutated c-KIT, offering an additional line of therapy for treatment-resistant GIST. | Available for licensing | |
| Oncology | HPK-1 | A novel, highly selective HKP1 inhibitor that drives an anti-tumour T-cell response by blocking HPK1, a negative regulator of T-cell signaling. This in turn combats the immune-suppressing microenvironment created by solid cancer tumours. | Available for licensing | |
| Oncology | ADC linker technologies | Antibody drug conjugates (ADC) linkers majorly influence an ADC's characteristics, including stability, release mechanism and hydrophilicity. Novel ADC linkers feature a two-stage reducible release mechanism that leverages high glutathione levels in cancer cells and is inherently more stable than other reducible mechanisms. | Available for licensing | |
| Oncology | Xmod - Xanthenone medicines on demand (KING) | A novel platform enables rapid development of xanthenone-based selective kinase inhibitors, offering higher specificity than current broad-spectrum inhibitors. Available are multiple assets at different stages that have been built from this platform. | Available for licensing | |
| Infectious disease | Eco-friendly Quaternary Ammonium Biocides | Quarternary ammonium biocides (QACs) raise concerns over environmental perisistance and toxicity. New eco-friendly QACs can be enzymatically broken down once diluted to sub-lethal concentrations, offering a safer alternative. | Available for licensing | |
| Ophthalmology | OcuNaera - preservative-free eye drop | A preservative-free, non-aqueous eye drop to relieve dry eye symptoms, without the need for preservatives and risk of infection. | Available for licensing | |
| Vaccines and drug delivery | Vaccine for Staphylococcus aureus |
A staphylococcal superantigen-like based vaccine for preventing staph infections.
Download PDF |
Available for licensing | |
| Vaccines and drug delivery | CLipPA: Cystine Lipidation on a Peptide or Amino acid |
A proprietary platform for the site-specific conjugation of lipids to peptides.
Download PDF |
Available for licensing | |
| Vaccines and drug delivery | Ester Bond Scaffolding |
A new protein platform technology: A novel 鈥榮uperglue鈥� utilising ester bonds to join multiple different units together to access many innovative applications.
Download PDF |
Available for licensing | |
| Regenerative and tissue engineering | Cell Replacement Therapy for Huntington鈥檚 Disease |
A novel cell replacement therapy for Huntington鈥檚 Disease directly reprogramming human skin cells into brain stem cells.
Download PDF |
Available for licensing | |
| Regenerative and tissue engineering | Kelch鈥檚 medium |
New cell growth media for keratinocytes: A cholera-toxin free and xenogeneic feeder cell-free media which maximises keratinocyte proliferation.
Download PDF |
Available for licensing | |
| Infectious diseases | Lipidated Polymyxins |
Novel analogue of polymyxin B as a new last-line therapy against antibiotic-resistant strains of Gram-negative bacteria.
Download PDF |
Available for licensing | |
| Regenerative and tissue engineering | Novel transparent protein biomaterials with versatile applications |
New biomaterials comprised of crystallin proteins being developed for ocular surgery and stem cell delivery applications.
Download PDF |
Available for licensing | |
| Ophthalmology | Diabetic Rat Strain | These rats develop hyperglycaemia and have retinal microaneurysms and macroaneurisms at four weeks of age. | Available for licensing | |
| Oncology | Novel therapy for glioblastoma | A new drug candidate for activating tumour cell death and improving uptake of chemotherapy drugs. | Available for licensing | |
| Oncology | c-Kit mutation selective inhibitor discovery programme |
Unique kinase ATP site-directed scaffold for the synthesis of highly potent c-Kit mutant selective inhibitors for cancer therapy.
Download PDF |
Available for licensing | |
| Oncology | HPK-1 Selective Inhibitor Discovery Program |
Selective HPK-1 antagonist for treating cancer. Related to the Kinase KING programme.
Download PDF |
Available for licensing | |
| Oncology | Kinase inhibitors for the next generation (Kinase KING) |
A platform for rapid development of highly selective next-generation protein kinase inhibitors.
Download PDF |
Available for licensing | |
| Oncology | Novel DNA analogues of duocarmycins as new toxins for ADCs |
Newly synthesised analogues of duocarmycin utilised as an optimised toxic payload in antibody-drug conjugates (ADCs) for cancer treatment.
Download PDF |
Available for licensing | |
| Oncology | Novel DNA-dependent protein kinase inhibitors |
Novel DNA-PK inhibitors and related hypoxia-activated prodrugs for sensitising tumour cells to radiotherapy by blocking a key DNA repair pathway.
Download PDF |
Available for licensing | |
| Oncology | FGFR inhibitors |
A targeted approach to deliver potent irreversible FGFR inhibitors utilising hypoxia selective activation for cancer therapy.
Download PDF |
Available for licensing | |
| Oncology | CSF鈥�1R inhibitor |
A unique scaffold and structure-based approach to synthesise highly potent CSF-1R inhibitors for cancer therapy.
Download PDF |
Available for licensing | |
| Oncology | TamoRx |
Developing immunotherapy to help patients鈥� immune systems destroy cancer cells.
|
Start-Up | |
| Neurological | Selective Antagonist of 5-HT2A receptor |
Novel compound exhibiting highly selective antagonism of the 5-HT2A receptor to treat psychiatric disorders.
Download PDF |
Available for licensing |
Medical devices, diagnostics, assays and digital health technologies
| Therapeutic Area | Name | Description | Status | Contact |
|---|---|---|---|---|
| Audiology | TrueSilence |
An evidence-based system that treats multiple aspects of tinnitus using a mobile device.
|
Start-Up | |
| Cardiology | HeartLab |
AI-powered heart scanning and reporting software.
|
Start-Up | |
| Cardiology | Atrial fibrillation: Real-time and robust mapping of heart activation |
Novel catheter-agnostic software platform to identify ablation targets for atrial fibrillation (AF) using signal processing and 3D voltage mapping to create fast substrate maps.
Download PDF |
Available for licensing | |
| Gastroenterology | Alimetry |
Alimetry鈥檚 unique technology non-invasively senses the motility of the stomach to detect the underlying mechanisms of gastric symptoms, informing personalised therapy.
|
Start-Up | |
| Gastroenterology | The Insides Company |
The Insides Company's flagship product, The Insides System, is a medical device that enables chyme to be reinfused into the intestine for enterostomy and enterocutaneous fistula patients.
|
Start-Up | |
| Immunology | Multiplexed tissue imaging |
A novel method for rapid staining and panel iteration for multiplexed tissue imaging.
Download PDF |
Available for licensing | |
| Immunology | Immune monitoring assays using spectral flow cytometry |
Advanced assays for cell characterisation and immunophenotype monitoring.
Download PDF |
Available for licensing | |
| Infectious diseases | Rheumatic fever: A new diagnostic tool |
A new streptococcal serological test to enable efficient and reliable diagnosis of rheumatic fever and post-streptococcal glomerulonephritis.
Download PDF |
Available for licensing | |
| Medical devices | Pressure Vessel Sensor | Implantable pressure monitoring system for detection of physiological fluid changes in blood, brain and bladder. | Available for licensing | |
| Ophthalmology | Toku Eyes |
Ophthalmic imaging device and computational modelling platform to diagnose and monitor eye diseases.
|
Start-Up | |
| Physiotherapy | JUNOFEM |
Pelvic floor pressure sensor and app to help with incontinence and pelvic organ prolapse.
|
Start-Up | |
| Surgery | Apercure Surgical | Radiological and surgical drain devices including a percutaneous catheter fixation device. | Start-Up | |
| Surgery | Avasa | An implantable arterial coupler to help surgeons reconnect microvascular arteries simply and efficiently in tissue transfer and transplant surgery | Start-Up | |
| Surgery | Surgical Canary | A medical device for the early detection of a leak from a gastrointestinal resection via extra-luminal colonic gas collection and sensing. | Available for licensing | |
| Medical devices | Embryo Assessment Technology, using AI | Embryo selection is a challenging task that is routinely performed by Clinics around the world. Using AI, we have developed an image-based tool that automatically selects those embryos with a higher chance of success. | Available for licensing | |
| Medical devices | Automated ventricular reconstruction | Manual segmentation of cardiac chambers is time-consuming and prone to error. Contrastingly, AI-based, automated reconstruction of 3D ventricular models now allows for efficient clinical measurements of heart function. | Available for licensing |